

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

## IntegraGen renews its agreement with the Institut Pasteur related to high-throughput sequencing for microbiology

---

### **IntegraGen announces the renewal of its partnership agreement with the Institut Pasteur until December 2021 related to high-throughput sequencing operations for microbiology activities carried out at the Institut Pasteur**

**Evry, France (March 11, 2020)** - **IntegraGen** (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the decryption of the human genome, which performs interpretable genomic analyzes for academic and private laboratories, and the Institut Pasteur, an institution recognized for public utility, whose mission is notably the prevention and fight against infectious diseases, by research, teaching and public health actions, today announced the renewal of an agreement through December 2021 related to IntegraGen's provision of high-throughput sequencing services for microbiology.

Through the renewal of the original agreement, which was signed in 2015, IntegraGen will continue its activities as operator of the P2M platform (Mutualized Microbiology Platform) for sequencing microorganisms for the National Reference Centers (CNR) hosted by the Institut Pasteur. This includes performing the daily technical sequencing operations essential for typing the strains organisms received by the CNR for the Institute and enabling the Institut Pasteur's scientists to receive data based on the latest sequencing methods.

**Vincent Enouf, Director of the P2M platform**, stated:

"Over the past five years, we have demonstrated our joint ability to provide National Reference Centers with a very efficient service for producing high-throughput sequencing data for microbiology samples, with tens of thousands DNA results obtained for both public health use and research applications. We are pleased to be able to continue this collaboration and benefit from IntegraGen's sequencing expertise and support for our efforts."

**Bernard Courtieu, President and CEO of IntegraGen**, added:

"We are particularly proud of the work we have accomplished over the past five years with the teams at the Institut Pasteur, a world reference for microbiology for more than a century. We are delighted to be able to continue our collaboration with the P2M teams where our services are increasing need and where the control of quality, deadlines and costs remains fundamental."

### **About IntegraGen**

IntegraGen is a company specializing in the analysis of the human genome and performs adaptive and quickly interpretable analyses for academic and private laboratories. For the management of cancers, which are characterized by a genetic disruption of cells, IntegraGen provides researchers and doctors with universal and individualized therapeutic guidance tools allowing them to adapt the treatment to the patient's genetic profile.

IntegraGen has forty-six employees and generated revenue of € 8.3 million in 2019. Based in the G nopol  d'Evry, IntegraGen is also located in the United States in Cambridge, MA. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

For more information, visit [www.integragen.com](http://www.integragen.com)



## About Institut Pasteur

An internationally renowned biomedical research center, Institut Pasteur, created in 1887 by Louis Pasteur, is a private foundation recognized for public utility. Its mission is to contribute to the prevention and fight against disease, in France and worldwide, through scientific and medical research, education and public health actions. Nearly 2,400 people work on its campus in Paris. In addition to research on the functioning of living organisms, a large part of his work is devoted to the study of infectious diseases, genetic and neurodegenerative diseases and certain cancers. The Institut Pasteur is at the heart of an international network which brings together 32 institutes on five continents. Since its creation, ten researchers have received the Nobel Prize in Physiology or Medicine.

For more information, visit [www.pasteur.fr](http://www.pasteur.fr)

## CONTACTS

### IntegraGen

Bernard COURTIEU  
President and CEO

Laurence RIOT LAMOTTE  
Chief Financial Officer  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel: +33 (0)1 60 91 09 00

### NewCap

Investor and Media Relations  
Louis-Victor DELOUVRIER  
[integragen@newcap.eu](mailto:integragen@newcap.eu)  
Tel: +33 (0)1 44 71 98 53